Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium (Q79899307)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 April 2004

Language	Label	Description	Also known as
English	Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium	scientific article published on 01 April 2004

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15073851%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15073851%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

phase III clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

8

object named as

George Wilding

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15073851%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

Robert Dreicer

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15073851%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Judith Manola

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15073851%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Bruce J Roth

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15073851%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

William A See

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15073851%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Steven Kuross

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15073851%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Martin J Edelman

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15073851%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Gary R Hudes

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15073851%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

1 April 2004

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15073851%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15073851%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

100

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15073851%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1639-1645

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15073851%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15073851%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20123

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20123

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20123

7 January 2021

based on heuristic

inferred from DOI database lookup

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20123

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20123

7 January 2021

based on heuristic

inferred from DOI database lookup

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20123

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20123

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20123

7 January 2021

based on heuristic

inferred from DOI database lookup

Exact significance testing to establish treatment equivalence with ordered categorical data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20123

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20123

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20123

7 January 2021

based on heuristic

inferred from DOI database lookup

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20123

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20123

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20123

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20123

7 January 2021

based on heuristic

inferred from DOI database lookup

Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20123

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20123

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.20123

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15073851%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15073851%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q79899307&oldid=1584453125"